Bare lymphocyte syndrome

Bare lymphocyte syndrome
ICD-10	D81.6
OMIM	604571 209920
DiseasesDB	29570 Template:DiseasesDB2
MeSH	D016511

WikiDoc Resources for Bare lymphocyte syndrome
Articles
Most recent articles on Bare lymphocyte syndrome Most cited articles on Bare lymphocyte syndrome Review articles on Bare lymphocyte syndrome Articles on Bare lymphocyte syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bare lymphocyte syndrome Images of Bare lymphocyte syndrome Photos of Bare lymphocyte syndrome Podcasts & MP3s on Bare lymphocyte syndrome Videos on Bare lymphocyte syndrome
Evidence Based Medicine
Cochrane Collaboration on Bare lymphocyte syndrome Bandolier on Bare lymphocyte syndrome TRIP on Bare lymphocyte syndrome
Clinical Trials
Ongoing Trials on Bare lymphocyte syndrome at Clinical Trials.gov Trial results on Bare lymphocyte syndrome Clinical Trials on Bare lymphocyte syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bare lymphocyte syndrome NICE Guidance on Bare lymphocyte syndrome NHS PRODIGY Guidance FDA on Bare lymphocyte syndrome CDC on Bare lymphocyte syndrome
Books
Books on Bare lymphocyte syndrome
News
Bare lymphocyte syndrome in the news Be alerted to news on Bare lymphocyte syndrome News trends on Bare lymphocyte syndrome
Commentary
Blogs on Bare lymphocyte syndrome
Definitions
Definitions of Bare lymphocyte syndrome
Patient Resources / Community
Patient resources on Bare lymphocyte syndrome Discussion groups on Bare lymphocyte syndrome Patient Handouts on Bare lymphocyte syndrome Directions to Hospitals Treating Bare lymphocyte syndrome Risk calculators and risk factors for Bare lymphocyte syndrome
Healthcare Provider Resources
Symptoms of Bare lymphocyte syndrome Causes & Risk Factors for Bare lymphocyte syndrome Diagnostic studies for Bare lymphocyte syndrome Treatment of Bare lymphocyte syndrome
Continuing Medical Education (CME)
CME Programs on Bare lymphocyte syndrome
International
Bare lymphocyte syndrome en Espanol Bare lymphocyte syndrome en Francais
Business
Bare lymphocyte syndrome in the Marketplace Patents on Bare lymphocyte syndrome
Experimental / Informatics
List of terms related to Bare lymphocyte syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bare lymphocyte syndrome is a condition caused by mutations in certain genes of the major histocompatibility complex or involved with the processing and presentation of MHC molecules. It is a form of severe combined immunodeficiency.

Classification

• Type 1: MHC class I
• Type 2: MHC class II

Presentation

The bare lymphocyte syndrome, type II (BLS II) is a rare recessive genetic condition in which a group of genes called major histocompatibility complex class II (MHC class II) are not expressed.

The result is that the immune system is severely compromised and cannot effectively fight infection. Clinically, this is similar to severe combined immunodeficiency (SCID), in which lymphocyte precursor cells are improperly formed. As a notable contrast, however, bare lymphocyte syndrome does not result in decreased B- and T-cell counts, as the development of these cells is not impaired.

Diarrhea can be among the associated conditions.

Genetics

BLS II

The genetic basis for BLSII is not due to defects in the MHC II genes themselves. The genetic basis is the result of mutations in genes that code for proteins (transcription factors) that normally regulate the expression (gene transcription) of the MHC II genes. That is, one of the several proteins that are required to switch on MHC II genes in various cells types (primarily those in the immune system) is absent. The genes responsible were cloned by the laboratories of Bernard Mach in Switzerland and Jeremy Boss at Emory University in Atlanta, Georgia.

Mutation in any one of four genes can lead to BLS II. The genes' names are:

• class II trans-activator (CIITA)
• regulatory factor of the X box 5 (RFX5)
• RFX-associated protein (RFXAP)
• RFX ankyrin repeats (RFXANK; also known as RFXB)

BLS I

BLS I, also called "HLA class I deficiency", which is much more rare, is associated with TAP2, TAP1, or TAPBP.

Treatment

Medical Therapy

Though BLSII is an attractive candidate for gene therapy, bone marrow transplant is currently the only treatment.